GOVERNMENT OF INDIA
ATOMIC ENERGY
LOK SABHA

UNSTARRED QUESTION NO:3704
ANSWERED ON:12.08.2015
Supply of Lutetium-177
Kirtikar Shri Gajanan Chandrakant;Singh Shri Kunwar Haribansh

Will the Minister of ATOMIC ENERGY be pleased to state:

(a)whether Radio Pharmaceutical Division of Bhabha Atomic Research Centre (BARC)has supplied Lutetium -177 DOTATATE medicine for neuroendocrine tumors cancer patients in All India Institute of Medical Sciences (AIIMS) hospital;

(b)if so, the effect of the above medicine to neuroendocrine tumor patients particularly with regard to pancreatic neuroendocrine tumors with liver" metastic;

(c)the procedure/cycle followed in this treatment;

(d)whether the said medicine has timely been supplied by the BARC to AIIMS in accordance with the cycle of medicine prescribed to the patients;

(e)if so, the details thereof and if not, the reasons therefor; and

(f)the steps taken/being taken by the Government for timely and adequate supply of this medicine to AIIMS and other central hospitals so that the patients are not put to any hardship?

Answer

THE MINISTER OF STATE FOR PERSONNEL, PUBLIC GRIEVANCES & PENSIONS AND PRIME MINISTER'S OFFICE (Dr. JITENDRA SINGH) :

(a)Bhabha Atomic Research Centre (BARC) through Board of Radiation & Isotope Technology (BRIT) supplies pharmaceutical grade Lutetium-177 CHLORIDE (177LuCl3) to AIIMS which is used for the preparation of Lutetium -177 DOTATATE. Preparation of Lutetium -177 DOTATATE is being carried out by Hospital Radiopharmacy of AIIMS.

(b)Lutetium-177 DOTATATE is reported to be effective in the treatment of pancreatic neuroendocrine tumors with liver metastasis.

(c)The exact procedure/cycle followed in this treatment is specific to patient's condition and is decided by the Nuclear Medicine Physician depending upon the extent of metastasis, age, body weight and patient medical conditions.

(d)&(e) The production schedule of this radiopharmaceutical ingredient is normally decided
based on the requirement of the hospitals. As per the production schedule, AIIMS is regularly procuring this radiopharmaceutical ingredient through Board of Radiation
and Isotope technology (BRIT). In the year 2015, AIIMS has asked pharmaceutical
grade 177LuCl3 on 13 occasions and the details of 177Lu activity supplied by BARC
through BRIT to AIIMS are given below:

Date Activity (milli-Curies)

05-01-2015 2000
19-01-2015 1300
23-02-2015 1650
10-03-2015 1350
30-03-2015 1400
07-04-2015 1134
27-04-2015 1350
05-05-2015 1900
25-05-2015 1200
01-06-2015 1300
29-06-2015 1500
06-07-2015 1500
27-07-2015 1450

(f)The Dhruva reactor in BARC is geared up to meet the increased production of Lu- 177 required for the preparation of the radiopharmaceutical to meet the growing demand of AIIMS as well as other nuclear medicine centres of India.

*****